

1 **Title. An ST131 clade and a Phylogroup A clade bearing a novel *Escherichia coli* O-antigen**
2 **cluster predominate among bloodstream *E. coli* isolates from southwest Nigeria hospitals.**

3
4 Ayorinde O. Afolayan¹, Aaron O. Aboderin², Anderson O. Oaikhen¹, Erkison Ewomazino
5 Odih¹, Veronica O. Ogunleye³, Adeyemi T. Adeyemo⁴, Abolaji T. Adeyemo⁵, Oyeniyi S.
6 Bejide¹, Anthony Underwood⁶, Silvia Argimón⁶, Monica Abrudan⁶, Abiodun Egwuenu⁷, Chikwe
7 Ihekweazu⁷, David M. Aanensen⁶ and Iruka N. Okeke^{1*}.

8
9 ¹Global Health Research Unit for the Genomic Surveillance of Antimicrobial Resistance,
10 Department of Pharmaceutical Microbiology, Faculty of Pharmacy, University of Ibadan, Oyo
11 State, Nigeria.

12 ²Department of Medical Microbiology and Parasitology, Obafemi Awolowo University Teaching
13 Hospitals Complex, Ile-Ife, Osun State, Nigeria.

14 ³Department of Medical Microbiology and Parasitology, University College Hospital, Ibadan,
15 Oyo State, Nigeria.

16 ⁴Department of Medical Microbiology and Parasitology, Obafemi Awolowo University Teaching
17 Hospitals Complex, Ile-Ife, Osun State, Nigeria.

18 ⁵Department of Medical Microbiology and Parasitology, University of Osun Teaching Hospital,
19 Osogbo, Osun State, Nigeria.

20 ⁶Centre for Genomic Pathogen Surveillance, Big Data Institute, University of Oxford, Old Road
21 Campus, Oxford, United Kingdom and Wellcome Genome Campus, Hinxton, UK.

22 ⁷Nigeria Centre for Disease Control, Jabi, Abuja, Nigeria.

23
24 ***Corresponding author:** Iruka N. Okeke. Department of Pharmaceutical Microbiology,
25 Faculty of Pharmacy, University of Ibadan, Oyo State, Nigeria. +234 805 328 1714.
26 iruka.n.okeke@gmail.com

27 **Abstract**

28 *Escherichia coli* bloodstream infections are typically attributed to a limited number of lineages
29 that carry virulence factors associated with invasion and, in recent years, are increasingly
30 multiply antimicrobial resistant. In Nigeria, *E. coli* is a common cause of bloodstream infections
31 but the identity of circulating clones is largely unknown and surveillance of their antimicrobial
32 resistance has been limited. We verified, susceptibility-tested and whole genome-sequenced 68
33 bloodstream *E. coli* isolates recovered between 2016 and 2018 at three sentinel sites in
34 southwestern Nigeria. Resistance to antimicrobials commonly used in Nigeria was high, reaching
35 100 % (n = 67) for trimethoprim, 92.5 % (n = 62) for ampicillin, 79.1 % (n = 53) for
36 ciprofloxacin, and 55.2 % (n = 37) for aminoglycosides. All the isolates were susceptible to
37 carbapenems and colistin. The strain set included isolates from globally disseminated high risk
38 clones including those belonging to ST12 (n=2), ST131 (n=12) and ST648 (n = 4). Twenty-three
39 (33.82%) of the isolates clustered within two clades. The first of these consisted of ST131
40 strains, comprised of O16:H5 and O25:H4 sub-lineages. The second was an ST10-ST167
41 complex clade comprised of strains carrying capsular genes that may have originated in
42 *Klebsiella*. We additionally determined that four ST90 strains from one sentinel represented a
43 retrospectively detected outbreak. Our data demonstrate that a broad repertoire of invasive *E.*
44 *coli* isolates cause bloodstream infections in southwest Nigeria. In addition to pandemic
45 lineages, particularly ST131, these include a previously undescribed lineage. Genomic
46 surveillance is valuable for tracking these and other clones and for outbreak identification.

47
48 **Keywords:** *Escherichia coli*, Genomic Surveillance, ST131, antimicrobial resistance, *cpsACP*,
49 Nigeria

51 **Data Summary**

52 Phylogenetic tree, clinical data, and epidemiological data were visualized using Microreact
53 (<https://microreact.org/project/NigeriaEcoliInvasive/d0dc3660>) and Phandango (for visualization
54 of pangenome, tree, and metadata). All the sequence data have been deposited in the ENA under
55 the project ID PRJEB29739 (<https://www.ebi.ac.uk/ena/browser/view/PRJEB29739>). Accessions
56 can be found in Table S6.

57

58

59 Introduction

60 Extra-intestinal pathogenic *Escherichia coli* (ExPEC) are responsible for the majority of
61 infections in the blood, urine, meninges, prostate, and other normally sterile sites [1–3].
62 Although typically initially acquired within the gastrointestinal tract (and less commonly via
63 genital route), these strains of *E. coli* differ from commensal and diarrhoeogenic *E. coli* in
64 possession of factors associated with systemic virulence [4, 5], allowing them to survive in
65 different extra-intestinal niches. Some of the virulence genes associated with ExPEC include
66 adhesins (*fim*, *pap*, *sfa*, *afa*), invasins (*ibeA*), iron acquisition genes (*ybt*, *iro*, *iuc*), toxins (*clb*,
67 *cnf*, *hly*, SPATE genes) and protectins (*traT*, *ompT*, *kpsMT*), among others [4, 5]. ExPEC also
68 often have K, O and H antigens that make them recognizable to *E. coli* experts and, in some
69 instances, assist them in evading immune responses. Virulence and AMR determinants, as well
70 as negative frequency-dependent selection, likely influence the stability of the most dominant
71 ExPEC groups, which are often multiply resistant [6], thereby sustaining the occurrence of extra-
72 intestinal diseases globally. In Africa, available data reveal that there is an upward trend in the
73 prevalence of globally dominant ExPEC lineages in humans [7] and animals [8], painting a grim
74 picture for disease and antimicrobial resistance.

75 Robust surveillance is urgently needed to tackle antimicrobial resistance in a more robust and
76 consistent manner within each country. Whole genome sequencing (WGS) has helped to provide
77 a clearer picture on the epidemiology of infectious diseases caused by ExPEC and has identified
78 a number of pandemic clones. Incorporation of WGS with existing epidemiological frameworks
79 in national public health institutes is critical for providing genomic context for prospective
80 surveillance and for designing and implementing AMR-eliminating strategies.

81 Although studies conducted in Africa and other low- and middle-income countries (LMICs) have
82 shown the abundance of invasive *E. coli* [9, 10], these studies are too few and far between so that
83 ExPEC and AMR epidemiology are poorly understood [7, 11]. In Nigeria, there is sparse
84 molecular information on ExPEC, but a few studies point to likely clonal expansion of resistant
85 lineages and local presence of pandemic clones of concern [12–16]. These studies provide
86 valuable information but represent an insufficient picture of ExPEC clones in Nigeria with few
87 data available from South. To extend the body of knowledge on genomic epidemiology of
88 ExPEC in south western Nigeria, including AMR patterns and mechanisms, we leveraged on our

89 existing genomic surveillance of bacterial AMR efforts by characterizing the genomes of
90 invasive isolates from tertiary hospitals in South-west Nigeria.

91

92 **Methodology**

93

94 **Species Validation and Antimicrobial Susceptibility Tests**

95 Sentinel hospital laboratories sent in anonymized clinical data and invasive *E. coli* isolates
96 collected between the years 2016 to 2018 to the National Reference Laboratory for verification
97 of isolate identity and antimicrobial susceptibility tests (AST). Isolate identity and AST were
98 achieved using the VITEK2 Instrument. Drugs tested include; amikacin (AMK), gentamicin
99 (GEN), ampicillin (AMP), amoxicillin/clavulanic acid (AMC), piperacillin/tazobactam (TZP),
100 cefuroxime (CXM), cefuroxime axetil (CXMA), cefepime (FEP), ceftriaxone (CRO),
101 cefoperazone/sulbactam (SFP), nitrofurantoin (NIT), nalidixic acid (NAL), ciprofloxacin (CIP),
102 ertapenem (ERT), imipenem (IPM), meropenem (MEM), and trimethoprim-sulphamethoxazole
103 (SXT). Resistance profiles were generated from VITEK2 AST data. Minimum Inhibitory
104 Concentration values were converted to RIS values and the bug-drug combination table was
105 generated using the AMR R package (v1.4.0; <https://github.com/msberends/AMR>) [17].
106 Antibiotic susceptibility patterns were determined in line with the CLSI 2019 standards [18].

107

108 **Biofilm Assay**

109 Following Wakimoto's procedure [19], we sub-cultured invasive *E. coli* strains overnight in LB
110 broth at 37°C with shaking at 160 rpm. Afterwards, we measured 190 µL of Dulbecco's
111 Modified Eagle's Medium (DMEM) containing 0.45 % glucose using a pipette into each well of
112 a 96-well plate (different plates were used for each time point (3h, 6h, 12h, 24 h)). Five µL of
113 each isolate was inoculated in triplicate per time point into a 96-well plate from the stock plate
114 and incubated at 37°C without shaking until each time point was reached. Absorbance at 595 nm
115 was taken on completion of time point.

116 We pipetted spent media out of the 96-well plates. Each well was washed with PBS three times,
117 fixed (10 mins, 200 µL of 75% ethanol), dried, and stained with 195 µL of 0.5 % crystal violet

118 for 5 minutes. This was followed by washing and drying of the plates. We added 200 μ L of 95%
119 ethanol to each well, allowed the wells to stand for 20 minutes at room temperature, and
120 determined absorbance with an enzyme linked immunosorbent assay (ELISA) plate reader at 570
121 nm. Biofilm index was defined using the average of the values for the optical density (OD) at
122 570 nm and 595 nm, and was calculated by dividing the OD values for each strain at a given
123 timepoint by the OD values of the negative control at the given timepoint [20].
124 Enteroaggregative *E. coli* strains 042 was used as positive control while *E. coli* K-12 DH5 α was
125 used as negative control.

126

127 **Haemolysis Test**

128 We sub-cultured invasive strains in LB broth at 37°C with shaking at 160 rpm overnight, and
129 transferred the mixture into 96-well plates where each well was assigned to each isolate. We
130 inoculated the surface of the blood agar with the invasive strains and control. Alpha haemolysis
131 and beta haemolysis is indicated by a green colouration and a clear zone around bacteria
132 colonies, respectively.

133

134 **DNA Extraction, Library Preparation, and Whole Genome Sequencing**

135 Genomic DNA was extracted following the protocol outlined in a previous report [21]. Briefly,
136 the Wizard DNA extraction kit (Promega; Wisconsin, USA; Cat. No: A1125) was used in the
137 extraction of genomic DNA of all isolates. A dsDNA Broad Range quantification assay was used
138 in the quantification of DNA extracts (Invitrogen; California, USA; Cat. No: Q32853). DNA
139 libraries were prepared and sequenced using the NEBNext Ultra II FS DNA library kit (New
140 England Biolabs, Massachusetts, USA; Cat. No: E6617L) and Illumina HiSeq X10 instrument
141 (Illumina, CA, USA), respectively.

142

143 **Genome Assembly and Speciation**

144 Raw sequence reads were assembled using the GHRU pipeline
145 (<https://gitlab.com/cgps/ghru/pipelines/assembly>) which is summarily explained by the GHRU
146 *de novo* assembly protocol (<https://www.protocols.io/view/ghru-genomic-surveillance-of->

147 [antimicrobial-resista-bpn6mmhe](#)). Speciation was possible using Bactinspector
148 (<https://gitlab.com/antunderwood/bactinspector/>), implemented within the GHRU pipeline.

149

150 **SNP Analysis and Phylogenetic Tree Generation**

151 The *Escherichia coli* reference genome GCF_000285655.3
152 (ftp://ftp.ncbi.nlm.nih.gov/genomes/all/GCF/000/285/655/GCF_000285655.3_EC958.v1/GCF_000285655.3_EC958.v1_genomic.fna.gz) was used to infer a whole-genome alignment of the
154 sequence reads. This step and other subsequent steps leading to the generation of a maximum-
155 likelihood phylogenetic tree was done per the GHRU Mapping-based phylogeny protocol
156 (<https://www.protocols.io/view/ghru-genomic-surveillance-of-antimicrobial-resista-bpn6mmhe>)
157 which summarizes the steps implemented within the GHRU SNP phylogeny pipeline
158 (https://gitlab.com/cgps/ghru/pipelines/snp_phylogeny).

159 Isolates that clustered closely within the phylogenetic tree, belonged to the same ST, and shared
160 similar resistance profiles, plasmid profiles, geography and dates of isolation, were investigated
161 further for clue on potential outbreaks. We selected the closest reference genome to the outbreak
162 isolates using Bactinspector, aligned the outbreak isolates (ST90) to the reference genome
163 (NZ_CP010140.1), used Gubbins [22] to mask recombinant regions, and calculated pairwise
164 SNP distances from the pseudo-genome alignment using FastaDist
165 (<https://gitlab.com/antunderwood/fastadist>). Phylogenetic tree, epidemiological data and in silico
166 data were visualized in Microreact [23] and Phandango [24].

167

168 **AMR gene, Virulence gene, and Plasmid Replicon Prediction**

169 The program SRST2 (v0.2.0; <https://github.com/katholt/srst2/>) [25] and the ARGannot database
170 (https://raw.githubusercontent.com/katholt/srst2/master/data/ARGannot_r3.fasta) was used to
171 screen raw sequence reads for the presence of acquired resistance genes. We also validated the
172 report/output by utilizing the GHRU AMR Pipeline
173 (https://gitlab.com/cgps/ghru/pipelines/dsl2/pipelines/amr_prediction) as explained briefly in this
174 protocol ([https://www.protocols.io/view/ghru-genomic-surveillance-of-antimicrobial-resista-](https://www.protocols.io/view/ghru-genomic-surveillance-of-antimicrobial-resista-bpn6mmhe)
175 [bpn6mmhe](#)). *AmpC1* and *AmpC2* were excluded from downstream analysis and visualization as

176 they are beta-lactamase genes present in almost all *E. coli* isolates and are unlikely to confer
177 antibiotic resistance in *E. coli* [26]. Overall plot of resistance determinants was constructed using
178 the *upset* function from the UpSetR package (v1.4.0) [27]. Plots of AMR genes stratified by
179 sequence type and sentinel site were constructed using the ggupset package (v0.3.0). Association
180 between virulence genes and phylogroups of *E. coli* was determined using the *fisher.test* function
181 from the built-in Stats package in R (v4.1.0). Bar plots were visualized using the *ggplot* function
182 from the Tidyverse package (v1.3.1) in R.

183 The raw reads were screened for virulence genes with the uses of the GHRU pipeline which
184 utilizes ARIBA [28] and the VFDB database [29]. Plasmid replicons were determined by
185 following the aforementioned GHRU protocol, which summarizes the use of ARIBA and the
186 PlasmidFinder database within the GHRU pipeline.

187

188 **MLST profiling**

189 Following the Achtman MLST scheme [30], multi-locus sequence types were determined using
190 the SRST2 program. We confirmed the results by using the GHRU MLST pipeline (also follows
191 the Achtman scheme) as summarized in the aforementioned GHRU protocol.

192

193 ***In silico* Serotyping and Phylogroup Determination**

194 The O and H serotypes of *Escherichia coli* were determined using the SRST2 program and the
195 EcOH database (<https://raw.githubusercontent.com/katholt/srst2/master/data/EcOH.fasta>). This
196 result was validated using ECTyper (https://github.com/phac-nml/ecoli_serotyping) and
197 SerotypeFinder (<https://bitbucket.org/genomicpidemiology/serotypefinder/src/master/>).
198 SerotypeFinder utilizes KMA [31] and BLAST+ [32] to predict *E. coli* serotypes from the
199 alignment of raw and assembled reads, respectively, against the SerotypeFinder database.
200 *Escherichia coli* genomes were assigned into phylogroups using ClermonTyping (v20.03) [33].

201

202 **Concordance**

203 The agreement between phenotypically-tested antimicrobial resistance and whole-genome
204 sequenced-predicted antimicrobial resistance was determined for beta-lactams, cephalosporins,
205 amikacin/kanamycin/gentamicin, trimethoprim, and the quinolones. Metrics such as sensitivity,
206 specificity, true positives, true negatives, false positives, and false negatives were determined
207 using a modified version (only input data was changed) of the R script ([https://gitlab.com/-
208 /snippets/2050300](https://gitlab.com/-/snippets/2050300), first used in a previous report) which utilizes the *epi.tests* function within the
209 epiR package (v2.0.26) for each antimicrobial tested. Here, “Sensitive” and “Intermediate”
210 values were combined, taking cognizance of the arguments for and against the use of the term
211 “Intermediate” in clinical settings [34].

212

213 **Genome Annotation, Comparative Genomics, and gene location prediction.**

214 Functional annotation of Onovel32 clade genomes was performed using Bakta v1.0.4 [35].
215 Genomes were compared and visualized using Artemis v18.1.0 [36], Artemis Comparison Tool
216 v18.1.0 [37], and Clinker v0.0.21 [38]. The mlplasmid web tool [39] was used to predict whether
217 clinically-relevant virulence genes were borne on plasmids or on chromosomes.

218

219 **Pangenome Analysis**

220 We utilized PROKKA-derived genome annotation files of each of the invasive *E. coli* genome
221 assemblies as input for the generation of a pangenome using Panaroo (v1.2.3) [40]. Phandango
222 [24] was used to visualize the pangenome, tree, and metadata. We used the
223 *find_clade_specific_genes* sub-command within the in-house script
224 (https://gitlab.com/bioinfo_erkison/panaroo_parser/-/blob/master/parse_panaroo.py) to identify
225 and annotate clade-specific genes (genes found within 95% of the isolates belonging to the clade
226 of interest and 5% of isolates outside the clade of interest).

227

228 **Results**

229 **Epidemiology and Species Identification**

230 Three hospital laboratories in South-west Nigeria submitted retrospective bloodstream
231 *Escherichia coli* isolates with clinical and epidemiological data between the years 2016 to 2018.
232 Available data showed that isolates were collected from patients aged 1 day to 71 years, with 17
233 (25%) of the isolates recovered from children under 60 days old (range 1- 20 days, median 9
234 days), who would be characterized as neonates. The isolates were submitted from the University
235 College Hospital (UCH; n = 22), Obafemi Awolowo University (OAU) Teaching Hospitals
236 Complex (n = 18), and Ladoke Akintola University (LAU; n = 28).

237 Of the 68 invasive isolates confirmed as *E. coli* by whole-genome sequencing (WGS), 48
238 (70.6%) and 64 (94.1%) were correctly identified as *E. coli* by the sentinel biochemical testing
239 and reference laboratory VITEK2, respectively. *Escherichia coli* isolates were often
240 misidentified as *Klebsiella pneumoniae* (n = 8) or *Citrobacter freundii* (n = 6) at the sentinel
241 laboratories, while the VITEK2 system misidentified *E. coli* as *Klebsiella pneumoniae* (n = 3) or
242 *Enterobacter aerogenes* (n = 1).

243

244 **Phylogroups, Serotypes, and Sequence Types of *E. coli* bloodstream isolates**

245 *E. coli* sent from all three hospital sentinel laboratories spanned all *E. coli* phylogroups, with 18,
246 15, 19, 8, 2, 1, and 5 *E. coli* genomes classified within phylogroups A, B1, B2, C, D, E, and F,
247 respectively. The most common sequence types (ST) among the 33 identified STs include;
248 ST131 (n = 12), ST156 (n = 5), and 4 each of ST10, ST167, ST410, ST648, and ST90. These 7
249 STs accounted for 54% of the *E. coli* isolates. Of these, only STs 131 and 167 were found across
250 the 3 sentinel sites (Figure 1a, Table S4). The three sentinel sites showed similar diversity of *E.*
251 *coli* belonging to several STs (OAU = 10 STs; LAU = 18 STs, UCH = 15 STs) (Table 1). While
252 ST131 genomes made up 63% of genomes within phylogroup B2 (the second most common
253 phylogroup), ST10 and ST167 genomes accounted for 44% of genomes within phylogroup A
254 (the most common phylogroup).

255 While none of the isolates were submitted as suspected outbreak strains, all four isolates
256 belonging to the related STs 90 serotyped *in silico* as O8:H9, and were recovered from LAU
257 within the same month (January, 2017). They carried the same plasmid profile (IncFI; IncFIA;
258 IncFIB_AP001918; IncQ1), AMR gene profile, and similar but not identical resistance profile
259 (Figure 1b; Table S4). These four isolates were resistant to trimethoprim, the quinolones,

260 gentamicin, cefuroxime axetil, and ampicillin (Figure 1b, Table S3b). Intra-cluster pairwise
261 comparison of SNPs revealed that two of the 4 isolates were identical while the other two
262 isolates differed from these two isolates by 11 SNPs (the genome with the extra set of accessory
263 genes) and 72 SNPs. Although these isolates were correctly identified within this sentinel site but
264 cluster was only recognized retrospectively, likely due to different beta lactam resistance
265 profiles.

266
267 ST131 was the most common sequence type detected and the 12 isolates belonging to this ST
268 clustered into two distinct lineages. They are the less-populated serotype H5 (n = 5; O16:H5)
269 lineage and the serotype H4 lineage (n = 7; O25:H4), henceforth referred to as the ST131 lineage
270 1 and ST131 lineage 2, respectively.

271 A total of 38 unique serotypes were identified and 25 O-groups. Of note was the most common
272 O-type, which was novel and identified in eleven isolates belonging to phylogroup A. These
273 ONovel:32 strains belonged to ST10 or ST167, or were single or double locus variants of these
274 STs. They included six ONovel32:H10 isolates as well as three H21 and one H4 –flagellin-
275 encoding strains. Along with one ONT:H10 strain that also belonged to ST10, they formed a
276 distinct clade on the phylogenetic tree (Figure 1a). Strains belonging to this cluster were
277 submitted from all three hospitals. Two of them were originally misclassified as *Klebsiella*
278 *pneumoniae* by VITEK at the reference laboratory level. Irrespective of whether the ST90
279 outbreak clone is discounted, the ONovel:32 clade and the ST131 clade were the most abundant.
280 Together they accounted for 32.4 % of the isolates and both clades were found in all three
281 hospitals (Figure 1a).

282 283 **Virulence Factor Profiles of the Bloodstream *E. coli* Isolates**

284 Diverse virulence genes were observed among the ExPEC genomes: 159 virulence-associated
285 (VAG) genes were found at least once in the 68 bloodstream isolates. Enterobactin genes (*entB*,
286 *entC*, *entE_1*, *entS*) and ferrienterobactin precursors and proteins (*fep* operon genes (ABCDEG)
287 and *fes_1*), were found in more than 95% of the isolates. The outer membrane hemin receptor
288 (*chu*), siderophores (*fyuA*, *irp*, *ybt*), intimin-like adhesin (*fdeC*), haemolysin (*hly*), aerobactin
289 (*iuc*), polysialic acid transport protein *kpsM_1*, pyelonephritis-associated pili *pap*, SPATE genes

290 (*sat*, *vat*), and plasmid-encoded *Shigella* enterotoxin *senB* were more abundant and significantly
291 more associated with phylogroup B2 than with phylogroups A, B1, and C (Fisher's exact Test, p
292 < 0.05 ; Figure 2a). Figure 2b shows that a wide range of biofilm-forming capacities were seen in
293 the subset of isolates tested with moderate or strong biofilm-formers being most common in
294 phylogroups B1 and B2 as well as the ST90 outbreak strain-containing phylogroup C.

295
296 There were a number of clade-specific or clade-predominant virulence factors. Phylogroup B2
297 isolates, comprised largely of ST131 strains, carried the highest number of virulence genes ($n =$
298 86 VAGs). Thirty-five virulence genes were significantly more common in ST131 isolates than
299 in non-ST131 isolates, where the genes of the outer membrane haem receptor (*chu*),
300 yersiniabactin (*ybt*), and pyelonephritis-associated pili (*pap*) operons compose 67% of these
301 genes in more than 84% of the ST131 isolates (Fisher's exact Test, $p < 0.05$; Fig. 3a). On the
302 other hand, 10 virulence genes were significantly more common in non-ST131 isolates than in
303 ST131 isolates, including 8 genes (*espX5*, *fimB_2*, and *gsp* variants) present in more than 78% of
304 the non-ST131 isolates, but less than 50% of ST131 isolates. The virulence genes *entD*, *espL*
305 variants, *espX* variants, *gnd*, and *ugd* were absent in ST131 isolates but were present in at least
306 27% of non-ST131 isolates, notably ONovel32 strains (Fig. 3a). Both lineages of ST131 share
307 common virulence genes, including; adhesins, yersiniabactin, aerobactin, enterotoxin, and
308 transport-associated genes. However, several virulence genes are unique to each lineage. For
309 example, the haemolysin (*hly*) carried by isolates within ST131 lineage 2 were absent in ST131
310 lineage 1. Also, two isolates within ST131 lineage 2 carried the cytotoxic necrotizing factor *cnf1*.
311 More than half of isolates within the ST131 lineage 2 harbour cluster_3, while at least 1 isolate
312 within ST131 lineage lineage 1 carried the *clbP* and *clbS* genes (Figure 3a and 3b).

313
314 None of the ONovel32 clade isolates carried alpha haemolysin or pyelonephritis associated pili
315 genes that were present in some of the other lineages. However, some virulence genes were
316 predominant among or restricted to ONovel32 strains (Figure 4a and 4b). These include the
317 *esp4L* type III secretion effector, which was more common among these isolates than other
318 phylogroup A strains as well as multiple genes encoding capsular modification enzymes. All the
319 ONovel32 strains and one associated ONT strain carried a *ugd* gene. The only other isolates in

320 this collection with this gene were three isolates belonging to the globally disseminated high risk
321 clone ST648 [41], known to possess biofilm-associated features that enhance pathogen
322 emergence and persistence in both the human body and the environment. The *ugd* gene is
323 associated with hypermucoviscosity and invasive virulence and the ONovel32 allele is 96%
324 identical to that from *K. pneumoniae* NTUH-K2044, a hypervirulent *K. pneumoniae* isolate [42]
325 and *K. variicola* (Accession number CP079802.1) capsular cluster *ugd* genes. Six of the
326 ONovel:32 strains (but not the ONT:H10 strain in the same clade) carried *cpsACP*, a
327 chromosomally-borne gene, which is predicted to encode a phosphatidic acid phosphatase (PAP2
328 Pfam 01569) family gene. PAP2 phosphatases replace phosphate groups on lipid A with amine
329 groups resulting in a positively charged lipidA that confers resistance to cationic peptides [43].
330 PAP2 phosphatases have been known to be transmitted horizontally solitarily or as part of
331 capsular clusters [44]. A BLAST search revealed that the ONovel32 PAP2 allele is 99.6%
332 identical to endogenous PAP2 genes from *Klebsiella variicola* (Accession number CP079802.1).
333 As shown in Figure 5, depicting the region for ONovel32 ST1284 strain OAU-VOA-056,
334 *cpsACP* is located within a capsular gene cluster identical to a *K. variicola* cluster and flanked by
335 a 5' IS3 transposase and a 3' IS1 protein InsB-encoding gene. At the opposite end of the cluster
336 is the *ugd* gene. The cluster shows G+C content and other base-pattern signatures that depart
337 from the *E. coli* flanking sequence (Figure 5a and 5b).

338
339 Observing that ONovel:32 cluster isolates, some of which were originally misclassified as
340 *Klebsiella*, showed mucoidity upon plate culture, we sought to determine whether these strains
341 had distinctive biofilm forming capacities. However, within the clade, although one *cpsACP*-
342 positive strain was the outlying exceptional biofilm former, *cpsACP*-positive strains showed
343 overall lower biofilm capacity. Median A_{570} in Figure 2 was 0.31 for phylogroup A strains
344 lacking *cpsACP* and 0.21 for those with the gene. Both ONovel:32 non-biofilm formers and two
345 of the three weak biofilm formers in this clade possessed the *cpsACP* gene.

346

347

348 **Resistance Profiles (RP) and Concordance with Predicted Antimicrobial Resistance**

349 Susceptibility testing of 67 out of the 68 isolates showed that, of the 16 antibiotics tested,
350 resistance to trimethoprim-sulfamethoxazole (n = 67; 100%), ampicillin (n = 62; 92.5%),
351 nalidixic acid (n = 57; 85.1%), and ciprofloxacin (n = 53; 79.1%) was commonly observed (Fig.
352 6a, Fig. 6b, Table S2). On the other hand, resistance to cefoperazone.sulbactam (n = 3; 4.5%)
353 was less common. All isolates were susceptible to amikacin, ertapenem, imipenem (one strain
354 showed “intermediate” phenotype), and meropenem. Resistance profiles were remarkably similar
355 among the three sentinels (Figure 6b). Resistance to trimethoprim/sulfamethoxazole among
356 isolates belonging to all 33 STs could be explained by the possession of *dfrA* (n = 54/67) and
357 *dfrB* (n = 2/67) genes. Ciprofloxacin resistance (23 STs) was largely attributable to mutation in
358 the quinolone resistance determining regions (QRDR) of *gyrA* (D87N, S83L), *parC* (E84A,
359 E84G, E84K, S57T, S80I), and/or *parE* (E460D, I355T, I529L, I529L, I464F, L416F, L445H,
360 S458A, S458T), with or without the presence of plasmid quinolone resistance genes (*qnrS*,
361 *qnrVC4*, *qepA*, *aac*-(6′)-*Ib-cr*). About 45% (n = 24/53) of isolates phenotypically resistant to
362 ciprofloxacin carried a combination of *aac*-(6′)-*Ib-cr5* gene and mutation in the QRDR regions
363 (*gyrA*, *parC*, and *parE*) (Figure 7a and 7b). The most common quinolone resistance gene profile
364 observed is the “*gyrA_D87N,gyrA_S83L,parC_S80I,parE_S458A*”, as observed in a quarter (n =
365 14/53) of isolates showing phenotypic resistance to ciprofloxacin.

366
367 Ampicillin resistance among isolates belonging to 29 STs could be explained by the carriage of a
368 range of beta-lactamase genes including *bla*_{TEM-1} (37/65 of isolates), *bla*_{TEM-40} (3 isolates), *bla*_{TEM-}
369 ₈₄ (2 isolates), *bla*_{TEM-135} (2 isolates), *bla*_{TEM-215} (1 isolate), or *bla*_{OXA-2} (co-occurring with *bla*_{TEM-}
370 ₉₀; 1 isolate). Extended-spectrum beta-lactam resistance likely resulted from *bla*_{CTX-M-15}, *bla*_{CTX-}
371 _{M-27}, and *bla*_{CMY-42} (Figure 8a and 8b) co-occurring largely with the plasmids Inc types
372 FIB_AP001918, FIA, IncFI, IncQ1, IncFII_p, and the col plasmid Col156. All isolates were
373 susceptible to ertapenem and meropenem (Table S2, Fig. S1a and S1b). One *bla*_{CTX-M-15} –positive
374 isolate from LAU (ST11025, B1, O51:H12) was categorized as showing intermediate to
375 imipenem but did not carry any carbapenemase-producing gene.

376 Of the 5 drug classes tested, the highest concordance between phenotypic resistance and
377 predicted antimicrobial resistance was observed for trimethoprim (100% concordance, TP =
378 67/67, Sensitivity = 100%, Specificity = NA) and the lowest concordance for drugs within the

379 aminoglycoside class (concordance = 55.22%, TP = 37/67, Sensitivity = 100%, Specificity = 0
380 %) (Table S3a).

381

382 **Multiple Antimicrobial Resistance**

383 We observed a total of 23 resistance profiles (RP) (Table S1) with resistance profiles in many
384 cases associated with specific STs (Table 1 and Table S4). Fifty-nine (88.06%) of the isolates
385 were resistant to at least one agent within at least three classes of antibiotics, fitting the multi-
386 drug resistant (MDR) definition of the international AMR community [45] (Table S1). Forty-
387 eight *E. coli* genomes carried genes conferring resistance to more than 5 antibiotic classes,
388 including; cephalosporins, sulphonamides, tetracyclines, and aminoglycosides. The three most
389 common beta-lactamase genes, *bla*_{TEM-1}, *bla*_{CTX-M-15}, and *bla*_{OXA-1} were carried by 37, 33, and 31
390 isolates belonging to 20 STs, 14 STs, and 11 STs, respectively. Isolates carrying the *bla*_{CTX-M-15}
391 gene also predominantly bore plasmid incompatibility group markers for FIB_AP001918 (n =
392 29/33), FIA (n = 24/33), FI (n = 20/33), and Col156 (n = 9). Isolates belonging to the most
393 frequent sequence types form the bulk of invasive isolates carrying ESBL genes or mutations in
394 the quinolone-resistance determining regions (*gyrA*, *parC*, *parE*), and the plasmid-mediated
395 quinolone resistance gene *aac(6')-Ib-cr*. Carbapenemase genes were conspicuously absent.

396

397 Resistance gene profiles differed significantly between the two ST131 clades. Unlike ST131
398 lineage 1 isolates, ST131 lineage 2 isolates did not carry any beta-lactamase gene besides *ampC*.
399 Within the ST131 lineage 1, two isolates did not carry genes conferring resistance/reduced
400 susceptibility to the aminoglycosides, phenicols, macrolides, and quaternary ammonium
401 compounds. Furthermore, the absence of the Col156, IncB_O_K_Z, and IncFI plasmids in these
402 two isolates seem to have been compensated by the possession of IncFIA, IncFII_p, and IncII
403 plasmids, noted to have been absent in the other three ST131 isolates within the ST131 lineage 1.

404

405 All the ONovel32 strains (but not the co-clustering ONT strain) carried 1 ESBL gene *bla*_{CTX-M-15},
406 and these strains also carried IncF plasmids, common among phylogroup A strains (Table S4,
407 Table S5). Every one of them carried the most common four resistance-conferring mutations in

408 the QRDRs (*gyrA_D87N,gyrA_S83L,parC_S80I,parE_S458A*) and seven, including the ONT
409 strain, carried *qepA4*. Four ONovel32 isolates additionally carried *aac-(6')-Ib-cr*, conferring
410 aminoglycoside and ciprofloxacin resistance, as well as horizontally-transmitted genes
411 conferring resistance to trimethoprim, chloramphenicol and tetracyclines were common
412 (Microreact link, Table S5).

413
414 Common to both the ST131 and the ONovel:32 clades is the high prevalence of *qacEdelta1* (n =
415 9 and 8, respectively) conferring resistance to quaternary ammonium compounds, commonly
416 used for disinfecting hospital surfaces and associated with class 1 integrons. Altogether, these
417 clades comprised 17 (42.50%) of 40 *E. coli* isolates carrying this gene.

418
419 **ST131 and ONovel32 clade-specific genes**

420 Pangenome analysis data of the 68 invasive isolates (Fig. 9) showed that of the 11715 gene
421 clusters detected, 3084, 267, 2379, and 5985 gene clusters were classified as core genes (present
422 in at least 67 out of 68), soft-core genes (present in 64-67 isolates), shell genes (9-64 isolates),
423 and cloud genes (< 9 isolates), respectively. There were 90, 28, 55, 159, 11, and 81 accessory
424 genes specific to the ST131 clade, ST156 clade, ST410 clade, ST648 clade, Onovel32 clade, and
425 ST90 clade, respectively. The ONovel32 clade specific genes are predicted to encode surface
426 factors (2), a ubiquinone biosynthesis O-methyltransferase, a transposase and hypothetical
427 proteins (7).

428
429
430 The comparatively large number of accessory genes unique to the ST131 include prophage
431 genes, adhesin genes, outer membrane-associated genes, DNA regulatory genes, IS transposase
432 genes and associated enzymes, hypothetical genes (n = 60/90), as well as transporters of
433 haemagglutinins, metals, and sugars. The two lineages of ST131 clade share 4116 core genes. On
434 the one hand, isolates within the ST131 lineage 1 carried 121 accessory genes, including; mobile
435 elements (group_1003, group_1164, group_1329, insB1, insCD1, ykfF, yjhR_2, ybcK, ybcQ,
436 group_1340, rrrD), and genes involved in multi-drug efflux (*emrE*), DNA binding (*arcA*,

437 argR_2), amino acid binding (argI_2), ATP binding (htpG_2, idnK), PTS permease activity
438 (frvA, frvB, sgcA_1), SOS response (umuC_4, group_1338). On the other hand, isolates within
439 the ST131 lineage 2 carried 284 accessory genes, including; prophage protein genes (gpFI_2),
440 mobile elements (group_1155, group_1348, group_1393, group_195, *insN2*, *intS*, *nohB*, *pine*,
441 *rrQ*, *rzpD*, *ydfD*, *ynfO*), and genes involved in structural molecule activity (*flg*, *fli*). A greater
442 proportion of hypothetical genes were identified in lineage 2 (~71%; n = 202/284) than lineage 1
443 (~38%; n = 47/121).

444 Onovel32 clade isolates carried 11 unique accessory genes, mainly associated with outer surface
445 structure including; the mitochondrial Ubiquinone biosynthesis O-methyltransferase, Spore coat
446 protein SA, UDP-glucose:(glucosyl)LPS alpha-12-glucosyltransferase, IS5 family transposase
447 IS903, and 7 hypothetical proteins.

448

449 **Discussion**

450 This research characterized 68 bloodstream *E. coli* isolates as an important first step in
451 understanding their epidemiology within south-west Nigeria. In this small collection, we
452 identified multiple clones of pandemic importance, and found two predominant clades. One of
453 these, comprised of two ST131 lineages is globally disseminated and this study illustrates its
454 importance in Nigerian health facilities. The second predominant clade does not feature in
455 present discourse on international ExPEC clones and represents strains belonging to ST10,
456 ST167 and related STs, which predominantly encode genes that could confer a novel O-antigen
457 type. In addition to these prominent clades, we identified strains belonging to major pandemic
458 ExPEC lineages, including ST12, ST73, and ST648, and their single locus variants. ST69,
459 ST95, and ST405 lineages were not detected but our sample is not very large and therefore our
460 findings are insufficient to rule them epidemiologically insignificant in our setting. We
461 additionally identified in the collection four ST90 strains that appear to represent an outbreak,
462 and related ST90 complex strains belonging to ST410. Our findings add to information that is
463 chronicling ExPEC lineages of importance within Nigeria [14–16, 46, 47], other parts of Africa
464 [16, 48], and other low- middle-income countries [16, 49].

465

466 Among ST131, we found both globally-disseminated lineages within our isolate collection. The
467 majority of haemolytic and pap gene bearing phylogroup B2 strains belonged to this ST.
468 Biofilm formation among these strains was common and associated with the *kpsD* gene, a known
469 contributor to biofilm formation [50]. The ST10, ST167 and related strains that comprised the
470 ONovel32 clade were distinguished by the presence of one of two variations of a capsular island
471 that has been well described in *Klebsiella* with biofilm formation among them being more
472 pronounced among strains carrying the *cpsACP*-containing portion of the island. While the
473 virulence of ST131 has been well described, features of this clade that cause it to predominate
474 remain unknown and further studies are required to understand its pathogenicity and selective
475 success in our setting.

476
477 High levels of phenotypic resistance to antibiotics within the trimethoprim (co-trimoxazole),
478 quinolone (nalidixic acid), fluoroquinolone (ciprofloxacin), cephalosporin (cefuroxime axetil),
479 and the aminoglycosides (gentamicin) observed among invasive isolates in this study
480 corroborates reports from previous studies [12, 46, 47] and pose a serious concern for clinical
481 therapeutics. *In silico* data confirm the abundance of genes conferring resistance, with many
482 isolates carrying more than one gene conferring resistance to a specific antimicrobial or class.
483 Before the turn of the millennium, resistance to many of the aforementioned antimicrobials was
484 rare in Africa. However, steady increase in the availability and use of these agents in the empiric
485 treatment of ExPEC-related infections has inevitably selected for AMR. The increased rate of
486 fluoroquinolone resistance in diarrhoeagenic *E. coli* and other enterobacteriaceae, for instance,
487 coincided with increased usage of the fluoroquinolones in Nigeria [51] and other parts of Africa
488 [7, 52]. While findings from a study conducted in Nigeria more than a decade ago [13]
489 concluded that nalidixic acid was still an effective antimicrobial, we observed in this study that
490 resistance to nalidixic acid is now common.

491 Similarly, cephalosporin resistance emerged and expanded much more in Africa than in other
492 parts of the world as these agents became the drug of choice for treating multi-drug resistant
493 pathogens [52]. Fluoroquinolone resistance has also been previously associated with the presence
494 of ESBL genes because ESBL genes are often borne on transferable large plasmids that co-host
495 some of the PMQR genes [53]. We observed the co-carriage of ESBL and fluoroquinolone

496 resistance genes in more than a quarter of the ExPEC isolates, and particularly in over-
497 represented lineages.

498

499 We find that both predominant lineages we have highlighted in this report show multiple
500 resistance. This has important implications for patients with life-threatening bloodstream
501 infections and provides a plausible explanation for their evolutionary success in our setting.
502 Resistance to antimicrobials used intensively in Nigeria (trimethoprim, aminopenicillins and
503 ciprofloxacin) was rife and resistance to the agents most frequently used empirically when blood
504 stream infections are suspected – second- and third-generation cephalosporins and
505 aminoglycosides was also worryingly common. While none of these clades showed carbapenem
506 or colistin resistance, these reserve antimicrobial classes are out of the reach of most patients
507 attending the three hospitals from which the strains were obtained.

508 Next-generation sequencing has emerged as a promising complement to clinical bacteriology as
509 it provides answers to medical conundrums as well as a more robust picture of the epidemiology
510 of infectious diseases. It can also reveal, as in this case, circulation of hitherto unrecognized
511 clones of concern. Although its integration into clinical diagnosis and patient care gaining
512 ground many parts of the world, its adoption in LMICs (and the rest of the globe) is still hindered
513 by lack of infrastructure, cost of implementing WGS, limited bioinformatics expertise and as yet
514 mildly inaccurate prediction of antimicrobial resistance [54, 55]. In our study, we observed
515 perfect concordance (100%) with phenotypic AST data for trimethoprim, but not for the
516 cephalosporins, the quinolones, or the aminoglycosides. This therefore shows that further
517 understanding of resistance mechanisms and routine AMR database update is needed to enhance
518 the feasibility of gradual and sustained integration of WGS into routine diagnosis.

519 Another advantage of next-generation sequencing is its potential in rapid detection of outbreaks
520 either retrospectively, or in real-time. We report a likely retrospective ST90 outbreak in LAU,
521 which would not have been detected using traditional diagnostic methods in the sentinel
522 laboratories. ST90 strains have variously been highlighted for their zoonotic potential and
523 association with device-related hospital outbreaks [56–58] and its epidemiology in our setting
524 remains to be understood. The adoption of genomic surveillance in diagnostic laboratories
525 within Nigeria will ensure that outbreaks of this and other clones can be detected in real time,

526 while definite tracking and containment of the spread of such clones will be achieved before
527 lives are lost.

528 This study has a few limitations. Blood culture is infrequently performed in Nigerian hospitals
529 and until recently, most isolates were not archived. Therefore, these isolates represent but a
530 fraction of the ExPEC likely to have infected patients in the three hospitals and may not be
531 representative. Our short-read data makes it impossible to accurately determine whether the
532 resistance genes are located on the bacterial chromosome or plasmids (or other mobile genetic
533 elements). For instance, pangenome analysis revealed that ST90 isolates (particularly the one
534 with the larger pangenome) carried numerous prophage genes that might mediate exchange of
535 AMR gene within and between clones and ONovel32 genomes are also phage-rich. ST131
536 isolates and other pandemic lineages also carried IS elements and mobile elements that can
537 potentially transfer genes from chromosomes to plasmids (or vice versa) or between strains.
538 However, we do not know whether these prophage genes or mobile genetic elements actually
539 carried AMR genes observed. In future, we will incorporate long read sequencing into our
540 prospective surveillance efforts in order to correctly identify plasmid-borne AMR genes.

541 In conclusion, this study provided hospital-specific information on the population structure of
542 ExPEC lineages needed to track pandemic lineages and guide infection disease control practices
543 in line with Nigeria's national action plan on antimicrobial resistance.

544

545 **Author Statements**

546 **Conceptualization:** David M. Aanensen, Iruka N. Okeke, Chikwe Ihekweazu; **Data curation:**
547 Ayorinde O. Afolayan, Anthony Underwood; **Formal Analysis:** Ayorinde O. Afolayan, Anthony
548 Underwood, Oyeniya S. Bejide, Iruka N. Okeke; **Funding acquisition:** David M. Aanensen,
549 Aaron O. Aboderin, Iruka N. Okeke; **Investigation:** Ayorinde O. Afolayan, Abiodun Ekwuenu,
550 Erkison Ewomazino Odih, Oyeniya S. Bejide, Aaron O. Aboderin, Iruka N. Okeke;
551 **Methodology:** Ayorinde O. Afolayan, Aaron O. Aboderin, Anderson O. Oaikhena, Erkison
552 Ewomazino Odih, Oyeniya S. Bejide, Veronica O. Ogunleye, Adeyemi T. Adeyemo, Abolaji T.
553 Adeyemo, Anthony Underwood, Silvia Argimón, Monica Abrudan, David M. Aanensen, Iruka
554 N. Okeke; **Project administration:** Abiodun Ekwuenu, Chikwe Ihekweazu, Aaron O. Aboderin,
555 Iruka N. Okeke; **Resources:** Anthony Underwood, Silvia Argimón, Veronica O. Ogunleye,

556 Adeyemi T. Adeyemo, Abolaji T. Adeyemo, David M. Aanensen, Iruka N. Okeke; **Software:**
557 Ayorinde O. Afolayan, Silvia Argimón, Anthony Underwood; **Supervision:** Aaron O. Aboderin,
558 Anthony Underwood, Silvia Argimón, David M. Aanensen, Iruka N. Okeke; **Validation:** All
559 authors; **Visualization:** Ayorinde O. Afolayan, Iruka N. Okeke; **Writing – original draft:**
560 Ayorinde O. Afolayan; **Writing – review & editing:** All authors.

561

562 **Acknowledgments/Funding**

563 We thank Damilola Q. Olaoye, Chinenye Ekemezie, Ifeoluwa Akintayo and Ifeoluwa Komolafe
564 for excellent technical assistance.

565 This work was supported by Official Development Assistance (ODA) funding from the National
566 Institute of Health Research [grant number 16_136_111] and the Wellcome Trust grant number
567 206194. INO was an African Research Leader supported by the UK Medical Research Council
568 (MRC) and the UK Department for International Development (DFID) under the MRC/DFID
569 Concordat agreement that is also part of the EDCTP2 program supported by the European
570 Union. The funders had no role in the content, crafting or submission of this paper.

571

572 **Ethics**

573 Isolates were obtained as part of the surveillance efforts in line with Nigeria's national action
574 plan and/or for bloodstream pathogen and *Escherichia coli* research. Ethical approval for
575 research using these isolates was obtained from the University of Ibadan/University College
576 Hospital and the Obafemi Awolowo University (OAU) Teaching Hospitals complex ethics
577 committees. Respective IRB registration numbers are UI/EC/15/093 and ERC/2017/05/06.

578

579 **Conflicts of Interest**

580 The authors have no conflicts of interest to declare.

581 **References**

582 1. **de Kraker MEA, Jarlier V, Monen JCM, Heuer OE, van de Sande N, et al.** The
583 changing epidemiology of bacteraemias in Europe: Trends from the European

- 584 antimicrobial resistance surveillance system. *Clin Microbiol Infect* 2013;19:860–868.
- 585 2. **Foxman B.** The epidemiology of urinary tract infection. *Nature Reviews Urology*
586 2010;7:653–660.
- 587 3. **Manges AR, Geum HM, Guo A, Edens TJ, Fibke CD, et al.** Global extraintestinal
588 pathogenic escherichia coli (Expec) lineages. *Clin Microbiol Rev*;32. Epub ahead of print
589 1 July 2019. DOI: 10.1128/CMR.00135-18.
- 590 4. **Johnson JR, Russo TA.** Molecular Epidemiology of Extraintestinal Pathogenic
591 Escherichia coli. *EcoSal Plus*;8. Epub ahead of print 8 February 2018. DOI:
592 10.1128/ecosalplus.esp-0004-2017.
- 593 5. **Sarowska J, Futoma-Koloch B, Jama-Kmiecik A, Frej-Madrzak M, Ksiazczyk M, et**
594 **al.** Virulence factors, prevalence and potential transmission of extraintestinal pathogenic
595 Escherichia coli isolated from different sources: Recent reports. *Gut Pathogens*
596 2019;11:10.
- 597 6. **McNally A, Kallonen T, Connor C, Abudahab K, Aanensen DM, et al.** Diversification
598 of colonization factors in a multidrug-resistant escherichia coli lineage evolving under
599 negative frequency- dependent selection. *MBio*;10. Epub ahead of print 1 March 2019.
600 DOI: 10.1128/mBio.00644-19.
- 601 7. **Chattaway MA, Aboderin AO, Fashae K, Okoro CK, Opintan JA, et al.**
602 Fluoroquinolone-resistant enteric bacteria in sub-saharan Africa: Clones, implications and
603 research needs. *Frontiers in Microbiology* 2016;7:558.
- 604 8. **Alonso CA, Zarazaga M, Ben Sallem R, Jouini A, Ben Slama K, et al.** Antibiotic
605 resistance in Escherichia coli in husbandry animals: the African perspective. *Letters in*
606 *Applied Microbiology* 2017;64:318–334.
- 607 9. **Khairy RM, Mohamed ES, Abdel Ghany HM, Abdelrahim SS.** Phylogenic
608 classification and virulence genes profiles of uropathogenic E. coli and diarrhegenic E.
609 coli strains isolated from community acquired infections. *PLoS One* 2019;14:e0222441.
- 610 10. **Forson AO, Tsidi WB, Nana-Adjei D, Quarchie MN, Obeng-Nkuramah N.**
611 Escherichia coli bacteriuria in pregnant women in Ghana: Antibiotic resistance patterns
612 and virulence factors. *BMC Res Notes* 2018;11:901.

- 613 11. **Huynh BT, Padget M, Garin B, Herindrainy P, Kermorvant-Duchemin E, et al.**
614 Burden of bacterial resistance among neonatal infections in low income countries: How
615 convincing is the epidemiological evidence? *BMC Infect Dis* 2015;15:127.
- 616 12. **Seni J, Peirano G, Okon KO, Jibrin YB, Mohammed A, et al.** The population structure
617 of clinical extra-intestinal *Escherichia coli* in a teaching hospital from Nigeria. *Diagn*
618 *Microbiol Infect Dis* 2018;92:46–49.
- 619 13. **Okonko IO, Donbraye-Emmanuel OB, Ijandipe LA, Ogun AA, Adedeji AO, et al.**
620 Antibiotics Sensitivity and Resistance Patterns of Uropathogens to Nitrofurantoin and
621 Nalidixic Acid in Pregnant Women with Urinary Tract Infections in Ibadan, Nigeria.
622 *Middle-East J Sci Res* 2009;4:105–109.
- 623 14. **Ogbolu DO, Piddock LJV, Webber MA.** Opening Pandora’s box: High-level resistance
624 to antibiotics of last resort in Gram-negative bacteria from Nigeria. *J Glob Antimicrob*
625 *Resist* 2020;21:211–217.
- 626 15. **Duru C, Olanipekun G, Odili V, Kocmich N, Rezac A, et al.** Molecular characterization
627 of invasive Enterobacteriaceae from pediatric patients in Central and Northwestern
628 Nigeria. *PLoS One* 2020;15:e0230037.
- 629 16. **Sands K, Carvalho MJ, Portal E, Thomson K, Dyer C, et al.** Characterization of
630 antimicrobial-resistant Gram-negative bacteria that cause neonatal sepsis in seven low-
631 and middle-income countries. *Nat Microbiol* 2021 64 2021;6:512–523.
- 632 17. **Berends MS, Luz CF, Friedrich AW, Sinha BNM, Albers CJ, et al.** AMR - An R
633 package for working with antimicrobial resistance data. *bioRxiv* 2019;810622.
- 634 18. **CLSI.** M100 Performance Standards for Antimicrobial Susceptibility Testing A CLSI
635 supplement for global application. Performance Standards for Antimicrobial Susceptibility
636 Testing Performance Standards for Antimicrobial Susceptibility Testing.
637 [https://www.academia.edu/41587236/M100_Performance_Standards_for_Antimicrobial_](https://www.academia.edu/41587236/M100_Performance_Standards_for_Antimicrobial_Susceptibility_Testing_A_CLSI_supplement_for_global_application_28th_Edition)
638 [Susceptibility_Testing_A_CLSI_supplement_for_global_application_28th_Edition](https://www.academia.edu/41587236/M100_Performance_Standards_for_Antimicrobial_Susceptibility_Testing_A_CLSI_supplement_for_global_application_28th_Edition) (2020,
639 accessed 6 August 2020).
- 640 19. **Wakimoto N, Nishi J, Sheikh J, Nataro JP, Sarantuya J, et al.** Quantitative biofilm
641 assay using a microtiter plate to screen for enteroaggregative *Escherichia coli*. *Am J Trop*

- 642 *Med Hyg* 2004;71:687–690.
- 643 20. **Naves P, Prado G Del, Huelves L, Gracia M, Ruiz V, et al.** Measurement of biofilm
644 formation by clinical isolates of *Escherichia coli* is method-dependent. *J Appl Microbiol*
645 2008;105:585–590.
- 646 21. **Afolayan AO, Oaikhena AO, Aboderin AO, Olabisi OF, Amupitan AA, et al.** Clones
647 and Clusters of Antimicrobial-Resistant *Klebsiella* from Southwestern Nigeria. *bioRxiv*
648 2021;2021.06.21.449255.
- 649 22. **Croucher NJ, Page AJ, Connor TR, Delaney AJ, Keane JA, et al.** Rapid phylogenetic
650 analysis of large samples of recombinant bacterial whole genome sequences using
651 Gubbins. *Nucleic Acids Res* 2015;43:e15.
- 652 23. **Argimón S, Abudahab K, Goater RJE, Fedosejev A, Bhai J, et al.** Microreact:
653 visualizing and sharing data for genomic epidemiology and phylogeography. *Microb*
654 *genomics* 2016;2:e000093.
- 655 24. **Hadfield J, Croucher NJ, Goater RJ, Abudahab K, Aanensen DM, et al.** Phandango:
656 an interactive viewer for bacterial population genomics. *Bioinformatics* 2018;34:292–293.
- 657 25. **Inouye M, Dashnow H, Raven LA, Schultz MB, Pope BJ, et al.** SRST2: Rapid genomic
658 surveillance for public health and hospital microbiology labs. *Genome Med*
659 2014;6:006627.
- 660 26. **Ingle DJ, Levine MM, Kotloff KL, Holt KE, Robins-Browne RM.** Dynamics of
661 antimicrobial resistance in intestinal *Escherichia coli* from children in community settings
662 in South Asia and sub-Saharan Africa. *Nat Microbiol* 2018;3:1063–1073.
- 663 27. **Conway JR, Lex A, Gehlenborg N.** UpSetR: An R package for the visualization of
664 intersecting sets and their properties. *Bioinformatics* 2017;33:2938–2940.
- 665 28. **Hunt M, Mather AE, Sánchez-Busó L, Page AJ, Parkhill J, et al.** ARIBA: Rapid
666 antimicrobial resistance genotyping directly from sequencing reads. *Microb Genomics*;3.
667 Epub ahead of print 1 October 2017. DOI: 10.1099/mgen.0.000131.
- 668 29. **Chen L, Yang J, Yu J, Yao Z, Sun L, et al.** VFDB: a reference database for bacterial
669 virulence factors. DOI: 10.1093/nar/gki008.

- 670 30. **Wirth T, Falush D, Lan R, Colles F, Mensa P, et al.** Sex and virulence in *Escherichia*
671 *coli*: An evolutionary perspective. *Mol Microbiol* 2006;60:1136–1151.
- 672 31. **Clausen PTL, Aarestrup FM, Lund O.** Rapid and precise alignment of raw reads
673 against redundant databases with KMA. *BMC Bioinformatics* 2018;19:1–8.
- 674 32. **Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, et al.** BLAST+:
675 Architecture and applications. *BMC Bioinformatics*;10. Epub ahead of print 15 December
676 2009. DOI: 10.1186/1471-2105-10-421.
- 677 33. **Beghain J, Bridier-Nahmias A, Nagard H Le, Denamur E, Clermont O.**
678 ClermonTyping: An easy-to-use and accurate in silico method for *Escherichia* genus strain
679 phylotyping. *Microb Genomics* 2018;4:e000192.
- 680 34. **Kahlmeter G, Giske CG, Kirn TJ, Sharp SE.** Point-counterpoint: Differences between
681 the European Committee on Antimicrobial susceptibility testing and Clinical and
682 Laboratory standards institute recommendations for reporting antimicrobial susceptibility
683 results. *J Clin Microbiol*;57. Epub ahead of print 1 September 2019. DOI:
684 10.1128/JCM.01129-19.
- 685 35. **Schwengers.** Bakta: Rapid & standardized annotation of bacterial genomes & plasmids.
686 GitHub: <https://github.com/oschwengers/bakta>.
- 687 36. **Rutherford K, Parkhill J, Crook J, Horsnell T, Rice P, et al.** Artemis: sequence
688 visualization and annotation. *Bioinformatics* 2000;16:944–945.
- 689 37. **Carver TJ, Rutherford KM, Berriman M, Rajandream M-A, Barrell BG, et al.** ACT:
690 the Artemis comparison tool. *Bioinformatics* 2005;21:3422–3423.
- 691 38. **Gilchrist CLM, Chooi Y-H.** clinker & clustermap.js: automatic generation of gene
692 cluster comparison figures. *Bioinformatics* 2021;37:2473–2475.
- 693 39. **Arredondo-Alonso S, Rogers MRC, Braat JC, Verschuuren TD, Top J, et al.**
694 mlplasmids: a user-friendly tool to predict plasmid- and chromosome-derived sequences
695 for single species. *Microb Genomics* 2018;4:e000224.
- 696 40. **Tonkin-Hill G, MacAlasdair N, Ruis C, Weimann A, Horesh G, et al.** Producing
697 polished prokaryotic pangenomes with the Panaroo pipeline. *Genome Biol* 2020;21:180.

- 698 41. **Schaufler K, Semmler T, Wieler LH, Trott DJ, Pitout J, et al.** Genomic and functional
699 analysis of emerging virulent and multidrug-resistant Escherichia coli lineage sequence
700 type 648. *Antimicrob Agents Chemother*;63. Epub ahead of print 1 June 2019. DOI:
701 10.1128/AAC.00243-19.
- 702 42. **Fang CT, Chuang YP, Shun CT, Chang SC, Wang JT.** A Novel Virulence Gene in
703 Klebsiella pneumoniae Strains Causing Primary Liver Abscess and Septic Metastatic
704 Complications. *J Exp Med* 2004;199:697–705.
- 705 43. **Touzé T, Tran AX, Hankins J V, Mengin-Lecreux D, Trent MS.** Periplasmic
706 phosphorylation of lipid A is linked to the synthesis of undecaprenyl phosphate. *Mol*
707 *Microbiol* 2008;67:264.
- 708 44. **Forde BM, Zowawi HM, Harris PNA, Roberts L, Ibrahim E, et al.** Discovery of mcr-
709 1 -Mediated Colistin Resistance in a Highly Virulent Escherichia coli Lineage .
710 *mSphere*;3. Epub ahead of print 31 October 2018. DOI: 10.1128/MSPHERE.00486-18.
- 711 45. **Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, et al.** Multidrug-
712 resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert
713 proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect*
714 2012;18:268–281.
- 715 46. **Aboderin OA, Abdu LR, Odetoyin BW, Lamikanra A.** Antimicrobial resistance in
716 Escherichia coli strains from urinary tract infections. *J Natl Med Assoc* 2009;101:1268–
717 1273.
- 718 47. **Onanuga A, Mahindroo J, Singh S, Taneja N.** Phenotypic and molecular
719 characterization of antimicrobial resistant escherichia coli from urinary tract infections in
720 port-harcourt, nigeria. *Pan Afr Med J*;34. Epub ahead of print 2019. DOI:
721 10.11604/pamj.2019.34.144.18182.
- 722 48. **Tegha G, Ciccone EJ, Krysiak R, Kaphatika J, Chikaonda T, et al.** Genomic
723 epidemiology of Escherichia coli isolates from a tertiary referral center in Lilongwe,
724 Malawi. *Microb Genomics* 2020;7:000490.
- 725 49. **Lim C, Takahashi E, Hongsuwan M, Wuthiekanun V, Thamlikitkul V, et al.**
726 Epidemiology and burden of multidrug-resistant bacterial infection in a developing

- 727 country. *Elife*;5. Epub ahead of print 6 September 2016. DOI: 10.7554/eLife.18082.
- 728 50. **Russo TA, Wenderoth S, Carlino UB, Merrick JM, Lesse AJ.** Identification, genomic
729 organization, and analysis of the group III capsular polysaccharide genes *kpsD*, *kpsM*,
730 *kpsT*, and *kpsE* from an extraintestinal isolate of *Escherichia coli* (CP9, O4/K54/H5). *J*
731 *Bacteriol* 1998;180:338–349.
- 732 51. **Lamikanra A, Crowe JL, Lijek RS, Odetoyin BW, Wain J, et al.** Rapid evolution of
733 fluoroquinolone-resistant *Escherichia coli* in Nigeria is temporally associated with
734 fluoroquinolone use. *BMC Infect Dis*;11. Epub ahead of print 7 November 2011. DOI:
735 10.1186/1471-2334-11-312.
- 736 52. **Musicha P, Cornick JE, Bar-Zeev N, French N, Masesa C, et al.** Trends in
737 antimicrobial resistance in bloodstream infection isolates at a large urban hospital in
738 Malawi (1998–2016): a surveillance study. *Lancet Infect Dis* 2017;17:1042–1052.
- 739 53. **Rawat D, Nair D.** Extended-spectrum β -lactamases in gram negative bacteria. *J Glob*
740 *Infect Dis* 2010;2:263.
- 741 54. **Mitchell SL, Simner PJ.** Next-Generation Sequencing in Clinical Microbiology: Are We
742 There Yet? *Clinics in Laboratory Medicine* 2019;39:405–418.
- 743 55. **Rossen JWA, Friedrich AW, Moran-Gilad J.** Practical issues in implementing whole-
744 genome-sequencing in routine diagnostic microbiology. *Clinical Microbiology and*
745 *Infection* 2018;24:355–360.
- 746 56. **Borges CA, Tarlton NJ, Riley LW.** *Escherichia coli* from Commercial Broiler and
747 Backyard Chickens Share Sequence Types, Antimicrobial Resistance Profiles, and
748 Resistance Genes with Human Extraintestinal Pathogenic *Escherichia coli*. *Foodborne*
749 *Pathog Dis* 2019;16:813–822.
- 750 57. **Gauthier L, Dortet L, Cotellon G, Creton E, Cuzon G, et al.** Diversity of
751 carbapenemase-producing *Escherichia coli* isolates in France in 2012–2013. *Antimicrobial*
752 *Agents and Chemotherapy*;62. Epub ahead of print 1 August 2018. DOI:
753 10.1128/AAC.00266-18.
- 754 58. **Sartori L, Fernandes MR, Ienne S, de Souza TA, Gregory L, et al.** Draft genome
755 sequences of two fluoroquinolone-resistant CTX-M-15-producing *Escherichia coli* ST90

756 (ST23 complex) isolated from a calf and a dairy cow in South America. *Journal of Global*
757 *Antimicrobial Resistance* 2017;11:145–147.
758
759

760 **Figures and Tables**


761 **Table 1: Distribution of Sequence Types (ST) and Resistance Profiles (RP) within Sentinel**
 762 **Sites**

Sentinel Site	No. of Isolates	No. of Observed STs	No. of Most Prevalent ST (number)	No. of Observed Resistance Profile	No. of Most Prevalent Resistance Profile (total number, STs (number))
OAU	18	10	ST131 (6)	9	RP-1: AMP CIP CRO CXM CXMA GEN NAL SXT (n = 5; ST131 (n = 3))
UCH	22	15	ST131 (5)	14	RP-5: AMP SXT (n = 4, ST12 (n = 2), ST942 (n = 2))
LAU	28	18	ST156 (4) & ST90 (4)	14	RP-2: AMP CIP CXMA GEN NAL SXT (Total = 7, ST156 (n = 3), ST90 (n = 3))

763


764

765 A



766

767 B



768

769 Figure 1a: Maximum likelihood SNP tree of bloodstream *E. coli* isolates sequenced for this
 770 study. Leaf tip colours differentiate the sentinel sites. The red box indicates the multisite ST131

771 clade and the ST10-ST167 clade is boxed in blue. A brown box marks the cluster from a single
772 site representing likely outbreak clone of ST90 (b) The ST90 likely outbreak cluster of O8:H9
773 strains, showing resistance and plasmid profiles


774 b: A likely outbreak clone of ST90 in a sentinel hospital. Legend shows serotype, resistance
775 profile and plasmid profile of ST90 *E. coli* isolates.

776

777


778

779 A.



780

781 B



782

783 Fig. 2: a. Comparison of virulence genes among isolates clustered within phylogroups A-F.
 784 Graph shows the prevalence of virulence factors in isolates within phylogroups A (n = 18),
 785 phylogroup B1 (n = 15), phylogroup B2 (n = 19), phylogroup C (n = 8), phylogroup D (n = 2),
 786 phylogroup E (n = 1), and phylogroup F (n = 5). Using Fisher's test ($p < 0.05$), only the virulence


787 genes significantly more prevalent in the phylogroups are shown. B. Biofilm formation in a
788 subset of strains, measured as A570 nm of crystal violet eluted from fixed and stained six-hour
789 biofilms. Each dot represents data from a single strain belonging to the phylogroup listed on the
790 X axis. Horizontal bars mark the median for each phylogroup, outliers inclusive due to the small
791 number of tested strains in each phylogroup.
792

793 A



794

795 B



796

797 Fig. 3a: Comparison of virulence genes between ST131 (n = 12) and non-ST131 (n = 35)
798 isolates. Non-ST131 isolates refer to isolates within STs 10, 156, 167, 410, 648, 90, 11025, 12,
799 1642*, 450, and 942. Using Fisher's test ($p < 0.05$), only the virulence genes significantly more
800 prevalent in the STs are shown.


801 b: Virulence factor profile of isolates belonging to ST131. Leaf tip colours differentiate the
802 sentinel sites; OAU (Red), UCH (Blue), LAU (Yellow). The presence or absence of a virulence
803 gene is indicated by a red or white colour on the heatmap, respectively.
804

805 A



806

807 B



808

0.050

809 Fig. 4a: Comparison of virulence genes between Onovel32 (n = 11) and non-Onovel32 (n = 57)


810 clade isolates. Using Fisher's test ($p < 0.05$), only the virulence genes significantly more

811 prevalent are shown. The *cpsACP* gene and the *ugd* gene bars were coloured red and magenta,
812 respectively.

813 b: Onovel32 clade isolates belonging to the sequence types ST10, ST167, and their locus variants
814 belong to phylogroup A. Leaf tip colours differentiate the sentinel sites; OAU (Red), UCH
815 (Blue), LAU (Yellow).


816

817 A



818


819 B



820


821 Figure 5a: Schematic cluster in ST1294 ONovel32 chromosome that includes the *ugd* and
 822 *cpsACP* genes. The 171 genes within the cluster are syntenic and identical with a cluster from
 823 *Klebsiella variicola* (Accession number: [CP079802.1](https://doi.org/10.1101/2021.11.07.21265989)). Above the schematic depiction of genes
 824 is a G+C content plot and mutational response index plot. (b) comparison of the ONovel32
 825 cluster with analogous cluster in *Klebsiella variicola* strain EMBL-1

826 A



827
828

B



829


830 Fig. 6a: Resistance Profile of ExPEC isolates. The main bar chart demonstrates the number of
831 ExPEC isolates with each combination of resistance to tested antibiotics, and is ordered in

832 descending order by the frequency of resistance profiles observed among 67 ExPEC isolates. The
 833 side bar chart demonstrates the number of isolates that are resistant to each of the named
 834 antibiotics. The dots and lines between dots at the base of the main bar chart (and the right side
 835 of the side bar chart) show the co-resistance status of the ExPEC isolates. All isolates were
 836 susceptible to Amikacin, Meropenem, Imipenem, and Ertapenem.


837 AMP = Ampicillin; CIP = Ciprofloxacin; CRO = Ceftriaxone; CXM = Cefuroxime; CXMA =
 838 Cefuroxime Axetil; FEP = Cefepime; GEN = Gentamicin; NAL = Nalidixic Acid; NIT =
 839 Nitrofurantoin; SFP = Cefoperazone/Sulbactam; SXT = Trimethoprim/Sulfamethoxazole; TZP =
 840 Piperacillin/Tazobactam

841 Fig. 6b: AMR phenotypes of ExPEC Isolates, stratified by Sentinel Site (LAU (n = 28), OAU (n
 842 = 22), UCH (n = 21)). The size of the coloured circles represent the proportion of isolates
 843 recovered from each sentinel site that demonstrated resistance to the tested antibiotics.

844
 845



846




847
 848 Fig. 7: Quinolone resistance gene combinations in ExPEC isolates. The upset plots show (a, b)
 849 the number of ExPEC isolates carrying each combination of genes conferring resistance to the
 850 quinolones (b), and is coloured by the proportion of observed phenotypic antimicrobial
 851 susceptibility, and is ordered in descending order by the frequency of resistance gene profiles
 852 observed. The side bar chart demonstrates the number of isolates that carry each of the resistance
 853 genes. The dots and lines between dots at the base of the main bar chart (and the right side of the
 854 side bar chart) show the co-resistance gene profile of the ExPEC isolates. From the legend of the
 855 coloured upset plot, NA means that phenotypic antimicrobial susceptibility data for the isolate is
 856 absent.

857


858

859 a)



860

861 b.)




862

863 Fig. 8: ESBL genes in ExPEC isolates. The upset plots demonstrate (a, b) the number of ExPEC
 864 isolates carrying each combination of genes conferring resistance to cephalosporins and (b), is
 865 coloured by the proportion of observed phenotypic antimicrobial susceptibility, and is ordered in

866 descending order by the frequency of resistance gene profiles observed. The side bar chart (a)
867 demonstrates the number of isolates that carry each of the resistance genes. The dots and lines
868 between dots at the base of the main bar chart (and the right side of the side bar chart) show the
869 co-resistance gene profile of the ExPEC isolates. From the legend of the coloured upset plot, NA
870 means that there is no available data on phenotypic antimicrobial susceptibility data for the
871 isolate.
872

873



874

875 Fig. 9: Maximum-likelihood phylogeny, core and accessory genome profiles of 68 invasive *E.*
876 *coli* whole-genome sequences visualized in combination with metadata (from left to right:
877 Sentinel, ST, phylogroup, biofilm index, haemolysis type, morphology, Serotype, and AMR gene
878 profiles). Presence of an AMR gene belonging to the named antibiotic class is indicated by a
879 maroon colour, while absence is indicated by a grey colour. Presence of a gene in the pangenome
880 is indicated by a blue colour while absence is indicated by a white colour. Highlighted
881 pangenome section show that ST131 (top) and ONovel32 (bottom) isolates have large
882 pangenomes.

883

884

885 **Supplementary Tables**

886 **Table S1: Resistance profiles of ExPEC isolates**

Resistance Profile (number)	Resistance Profile code
AMP CIP CRO CXM CXMA GEN NAL SXT (10)	RP-1
AMP CIP CXMA GEN NAL SXT (8)	RP-2
AMP CIP CRO CXM CXMA FEP GEN NAL SXT (6)	RP-3
AMP CIP NAL SXT (6)	RP-4
AMP SXT (4)	RP-5
SXT (4)	RP-6
AMP CIP CRO CXM CXMA FEP GEN NAL SFP SXT TZP (3)	RP-7
AMP CIP CRO CXM CXMA FEP NAL SXT (3)	RP-8
AMP CIP CRO CXM CXMA NAL SXT (3)	RP-9
AMP NAL SXT (3)	RP-10
AMP CIP CRO CXM CXMA FEP GEN NAL NIT SXT (2)	RP-11
AMP CIP CRO CXM CXMA FEP GEN NAL SXT TZP (2)	RP-12
AMP CIP CXM CXMA NAL SXT TZP (2)	RP-13
AMP CIP CXMA GEN NAL NIT SXT (2)	RP-14
AMP CIP CRO CXM CXMA GEN NAL SXT TZP (1)	RP-other
AMP CIP CRO CXM CXMA SXT (1)	RP-other
AMP CIP CRO CXM CXMA GEN NAL SXT TZP (1)	RP-other
AMP CIP CXMA NAL SXT (1)	RP-other
AMP CIP CXMA NAL SXT TZP (1)	RP-other
AMP CIP GEN NAL SXT (1)	RP-other
AMP CXMA SXT (1)	RP-other
AMP GEN NAL SXT TZP (1)	RP-other
NAL SXT TZP (1)	RP-other

887

888

889 **Table S2: Summary of Antibiotic Susceptibility Test data showing the number of *E. coli***
 890 **isolates that were resistant to the named antibiotics.**

Drug class	Drug	Resistance % (resistance (n)/species (n))
Aminoglycosides	Gentamicin (GEN)	55.20% (37/67)
Beta-lactams/penicillins	Ampicillin (AMP)	92.50% (62/67)
	Piperacillin/tazobactam (TZP)	17.90% (12/67)
Cephalosporins (2nd gen.)	Cefuroxime (CXM)	50.70% (34/67)
	Cefuroxime Axetil (CXMA)	70.10% (47/67)
Cephalosporins (3rd gen.)	Cefoperazone.Sulbactam (SFP)	4.50% (3/67)
	Ceftriaxone (CRO)	46.30% (31/67)
Cephalosporins (4th gen.)	Cefepime (FEP)	23.90% (16/67)
Other antibacterials	Nitrofurantoin (NIT)	6.00% (4/67)
Quinolones	Ciprofloxacin (CIP)	79.10% (53/67)
	Nalidixic acid (NAL)	85.10% (57/67)
Trimethoprim	Trimethoprim/sulfamethoxazole (SXT)	100.0% (67/67)

Table S3: Degree of Agreement between phenotypic antimicrobial susceptibility tests and genotypic predicted antimicrobial resistance

drug	Tests (N)	concordance	TP	FP	TN	FN	specificity	Specificity lower limits	Specificity upper limits	sensitivity	Sensitivity lower limits	Sensitivity upper limits
Aminoglycosides	67	0.552238806	37	30	0	0	0	0	0.115703308	1	0.905109413	1
Beta-lactams	67	0.71641791	45	1	3	18	0.75	0.19412045	0.993690537	0.714285714	0.586538974	0.821070793
Cephalosporins	67	0.686567164	46	20	0	1	0	0	0.168433471	0.978723404	0.887062283	0.999461468
Quinolones	67	0.865671642	56	7	2	2	0.222222222	0.028144973	0.600093574	0.965517241	0.880922689	0.995796353
Trimethoprim	67	1	67	0	0	0	NA	0	1	1	0.946430346	1

(Table S3b). **Degree of Agreement between phenotypic antimicrobial susceptibility tests and genotypic predicted antimicrobial resistance in isolates belonging to the ST131, ST90, and ST10-167 clades.**

id	ST	Aminoglycosides AMR	Aminoglycosides AST	Betalactam AMR	Betalactam AST	Cephalosporins AMR	Cephalosporins AST	Quinolones AMR	Quinolones AST	Trimethoprim AMR	Trimethoprim AST
G18484079	1284	R	S	S	R	R	R	R	R	R	R
G18503180	131	R	R	S	R	R	R	R	R	R	R
G18503191	131	R	S	S	R	R	R	R	R	R	R
G18503409	131	R	R	R	R	R	R	R	R	R	R
G18503422	131	R	R	R	R	R	R	R	R	R	R
G18503432	131	R	R	R	R	R	R	R	R	R	R
G18584035	131	R	R	S	R	R	R	R	R	R	R
G18584046	131	R	R	S	R	R	R	R	R	R	R
G18584087	131	R	S	R	R	R	S	R	R	R	R
G18584153	131	R	R	S	R	R	R	R	R	R	R
G18584154	131	R	R	S	R	R	R	R	R	R	R
G18584155	131	R	S	R	S	R	S	R	S	R	R
G18584158	10	R	R	R	R	R	R	R	R	R	R
G18584159	167	R	R	R	R	R	R	R	R	R	R

G18584161	167	R	R	R	R	R	R	R	R	R	R
G18584163	10	R	R	R	R	R	R	R	R	R	R
G18600004	10	R	S	R	R	R	R	R	R	R	R
G18600024	131	R	R	S	R	R	R	R	R	R	R
G18600026	167	R	R	R	R	R	R	R	R	R	R
G18600033	617	R	R	S	R	R	R	R	R	R	R
G18600048	44	R	R	S	R	R	R	R	R	R	R
GI8584164	10	R	S	R	R	S	R	R	R	R	R
G18600002	90	R	R	R	R	R	R	R	R	R	R
G18600020	90	R	R	R	R	R	R	R	R	R	R
G18600022	90	R	R	R	R	R	R	R	R	R	R
G18600030	90	R	R	R	R	R	R	R	R	R	R

Table S4: Genotypic characteristics of the most common STs in the invasive microbial population.

ST (number of strains)	Phylo- group	Sentinel Site (number)	Serotype (number)	Most Prevalent Resistance Profile (number)	Most Prevalent AMR gene profile (number)	Most prevalent plasmid replicon profile (number)
ST131 (12)	B2	OAU (6) UCH (5) LAU (1)	O16:H5 (5), O25:H4 (7)	RP-1: AMP CIP CRO CXM CXMA GEN NAL SXT (5)	aac(6')-Ib-cr5; Aac3-IIa*,Aac6Ib-cr*,AadA5; blaCTX-M-15,blaEC-5,blaOXA-1; CatB4_602; DfrA17; gyrA_D87N,gyrA_S83L,parC_E84V,parC_S80I,parE_I529L; MphA_1663; qacEdelta1; SulI; TetA (n = 3) and aac(6')-Ib-cr5; Aac3-IIId*,Aac6Ib-cr*,AadA5,StrA*,StrB*; blaCTX-M-15,blaEC-5,blaOXA-1; blaTEM-40; CatB4; DfrA17; gyrA_S83L,parE_I529L; MphA; qacEdelta1; SulII,SulI; TetA (3)	Col156; IncB_O_K_Z; IncFI; IncFIB_AP001918 (3) and Col156; IncFI; IncFIA; IncFIB_AP001918 (3)
ST10 (4)	A	OAU (3) LAU (1)	Onovel32:H10 (3), H10 (1)	RP-14: AMP CIP CXMA GEN NAL NIT SXT (2)	Each isolate had a unique AMR gene profile	IncFI; IncFIA; IncFIB_AP001918; IncQ1 (2)
ST156 (5)	B1	LAU (4) UCH (1)	H45 (1), O174:H28 (1), O54:H28 (2),	RP-2: AMP CIP CXMA GEN NAL SXT (3)	Aac3-IIId*,StrA*,StrB; blaEC-18; blaTEM-1; DfrA17; gyrA_D87N,gyrA_S83L,parC_S80I; qepA8; SulII*; TetB* (3)	IncFIA; IncFIB; IncQ1 (3)

		O76:H30 (1)							
ST167 (4)	A	OAU (2) LAU (1) UCH (1)	Onovel32:H 10 (2), Onovel32:H 21 (2)	Each isolate had a unique AST profile	Aac3-IId*; blaCTX-M-15,blaEC-15; gyrA_D87N,gyrA_S83L,parC_S80I,parE_S458A; TetB* (2)	blaTEM-1;	IncFI; IncFIA; IncFIB_AP001918 (3)		
ST410 (4)	C	LAU (2) UCH (2)	O8:H9 (2), Onovel14:H 9 (2)	RP-9: AMP CIP CRO CXM CXMA NAL SXT (2)	Each isolate had a unique AMR gene profile		Col_MG828; IncFI; IncFIA; IncFIB_AP001918 (2)		
ST648 (4)	F	LAU (3) OAU (1)	O153var1:H 6 (1), O8:H4 (3)	RP-7: AMP CIP CRO CXM CXMA FEP GEN NAL SFP SXT TZP (2)	aac(6')-Ib-cr5; Aac3-IIa*,Aac6Ib-cr*,AadA5; 42,blaCTX-M-15,blaEC-19,blaOXA-1; CatA1*,CatB4; gyrA_D87N,gyrA_S83L,parC_S80I,parE_S458A; MphA; qacEdelta1; SullI; TetB* (2).	blaCMY- 42,blaTEM-1; DfrA17;	Col_BS512; Col_BS512__1; IncFIA; IncFIB_AP001918; IncFII_p; IncI1 (2)		
ST90 (4)	C	LAU (4)	O8:H9 (4)	RP-2: AMP CIP CXMA GEN NAL SXT (3)	aac3-IId, aac6Ib-cr, strA, strB; blaOXA-1; gyrA_D87N, gyrA_S83L, parC_S80I, parE_S458A; dfrA17; mphA; sullI; tetB (4).	blaTEM-1; blaEC-16,	IncFI; IncFIA; IncFIB_AP001918; IncQ1 (4)		
ST1102 5 (2)	B1	LAU (2)	O51:H12 (2)	RP-11: AMP CIP CRO CXM CXMA FEP GEN NAL NIT SXT (1)	aac3-IIa, aadA5, strA, strB; blaEC-16; gyrA_D87N, gyrA_S83L, parC_S80I, parE_S458T; catA1; dfrA17; sullI; tetB; qacE (2)	blaTEM-1; blaCTX-M-15,	IncFIA; IncFIB_AP001918; IncFII_p; IncI1; IncQ1 (2)		
				and					

				RP-other: AMP CXMA SXT (1)			
ST12 (2)	B2	UCH (2)	O4:H1 (2)	RP-5: AMP SXT (2)	strA, strB; blaTEM-1; blaCTX-M-15, blaEC-5; gyrA_S83L; dfrA7; sulI, sulII; tetA; qacEdelta1 (2)	IncQ1; IncY (2)	
ST1642 * (2)	B1	OAU (1) UCH (1)	O8:H7 (2)	RP-1: AMP CIP CRO CXM CXMA GEN NAL SXT (1) and RP-4: AMP CIP NAL SXT (1)	aac3-IIId, aac6Ib-cr, strA, strB; blaTEM-1; blaCTX-M-15, blaEC-18, blaOXA-1; gyrA_D87N, gyrA_S83L, parC_S80I, parE_E460D; catB4; mphA; sulII.	Col8282; IncFI; IncFIA; IncFIB_AP001918; IncFII; IncQ1	
ST450 (2)	A	LAU (1) UCH (1)	O12:H16 (1), O45:H16 (1)	RP-4: AMP CIP NAL SXT (2)	aadA5, strA, strB; blaTEM-1; blaEC-15; gyrA_D87N, gyrA_S83L, parC_S80I, parE_I464F/ parE_S458A; CatA1; dfrA17; sulII; tetA; qacEdelta1	Col156; Col_BS512; Col_BS512__1; Col_MG828; IncFIA; IncFIB_AP001918; IncFII_p (1); OR Col156; IncFI; IncFIA; IncFIB_AP001918 (1)	

ST942 (2)	B1	UCH (2)	O163:H28 (2)	RP-5: AMP SXT (2)	strA, strB; blaTEM-1; blaEC-16; qnrS1; floR; sulII; tetA (2)	pO111 (2)
--------------	----	---------	-----------------	-------------------	---	-----------

Table S5: Genotypic characteristics of Onovel32 genomes in the invasive microbial population.

id	Sentinel	ST	Serotype	Resistance gene profile	plasmid_profile
G18484079	OAU	1284	Onovel32:H21	AadA2*, StrA*?,StrB; blaCTX-M-15,blaEC-15; CatA2*; DfrA12; gyrA_D87N,gyrA_S83L,parC_S80I,parE_S458A; MphA; qacEdelta1; qepA4; SulII, SullI; TetB*	IncFI; IncFIA; IncFIB_AP001918; IncX1; IncX1_1
G18503408	UCH	167	Onovel32:H10	AadA2*,StrA*,StrB*; blaCTX-M-27, blaEC-15; CatA1*,CatA2*; DfrA12; gyrA_D87N,gyrA_S83L,parC_S80I,parE_S458A; MphA*?; qacEdelta1; qepA4; SulII, SullI; TetA,TetB*,TetM*	IncFI; IncFIA; IncFIB_AP001918; IncX2
G18584158	OAU	10	Onovel32:H10	aac(6)-Ib-cr5; Aac3-IId*,Aac6Ib-cr* AadA5,StrA*,StrB; blaOXA-1; blaTEM-84; CatA1*,CatB4; DfrA17; gyrA_D87N,gyrA_S83L,parC_S80I,parE_S458A; MphA; qacEdelta1; SulIII*; TetB*	IncFI; IncFIA; IncFIB_AP001918; IncQ1
G18584159	OAU	167	Onovel32:H21	Aac3-IId*; blaCTX-M-15, blaEC-15; blaTEM-1; gyrA_D87N,gyrA_S83L,parC_S80I,parE_S458A; TetB*	IncFI; IncFIA; IncFIB_AP001918
G18584161	OAU	167	Onovel32:H21	Aac3-IId*; blaCTX-M-15, blaEC-15; blaTEM-1;	IncFI; IncFIA;

				gyrA_D87N,gyrA_S83L,parC_S80I,parE_S458A; TetB*	IncFIB_AP001918
G18584163	OAU	10	Onovel32:H10	aac(6')-Ib-cr5; Aac3-IId*,Aac6Ib-cr*,AadA5,StrA*,StrB; blaOXA-1; blaTEM-84; CatA1*,CatB4*; DfrA17; gyrA_D87N,gyrA_S83L,parC_S80I,parE_S458A; MphA; qacEdelta1; SulIII*; TetB*	IncFI; IncFIA; IncFIB_AP001918; IncQ1
G18600004	LAU	10	Onovel32:H10	AadA1*?,StrA*,StrB*; blaOXA-1; blaTEM-1; DfrA14; gyrA_D87N,gyrA_S83L,parC_S80I,parE_S458A; qepA4; SulII	IncFI; IncFIA; IncFIB_AP001918
G18600026	LAU	167	Onovel32:H10	Aac3-IId*; blaEC-15; blaTEM-1; CatA1*; DfrA12; gyrA_D87N,gyrA_S83L,parC_S80I,parE_S458A; MphA; qacEdelta1; qepA4; SulI; TetB*	IncFI; IncFIA; IncFIB_AP001918
G18600033	LAU	617	Onovel32:H10	aac(6')-Ib-cr5; Aac3-IIa*,Aac6Ib-cr*,AadA5,StrA*?,StrB; blaCTX-M-15,blaEC-15,blaOXA-1; CatB4; DfrA17; gyrA_D87N,gyrA_S83L,parC_S80I,parE_S458A; MphA; qacEdelta1; SulII, SulI; TetB*	IncFI; IncFIA; IncFIB_AP001918
G18600048	LAU	44	Onovel32:H4	aac(6')-Ib-cr5; Aac3-IIa*,Aac6Ib-cr*,AadA5;	Col_MG828; IncFI;

				blaCTX-M-15,blaOXA-1; CatB4; DfrA17; gyrA_D87N,gyrA_S83L,parC_S80I,parE_S458T; qacEdelta1; Sull; TetB*	IncFIB_AP001918; IncX3
GI8584164	OAU	10	H10	AadA2*,StrA*,StrB,CatA1*; blaTEM-1; DfrA12; gyrA_D87N,gyrA_S83L,parC_S80I,parE_S458A; MphA,QepA2*; qacEdelta1; qepA4; SulII*,SulI; TetB*	ColRI; Col_BS512; IncP_6